Last reviewed · How we verify

Biotec Pharmacon ASA — Portfolio Competitive Intelligence Brief

Biotec Pharmacon ASA pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
SBG SBG phase 3 BMP antagonist Bone morphogenetic protein (BMP) signaling Orthopedics / Rare Genetic Disorders
Soluble beta-glucan (SBG) Soluble beta-glucan (SBG) phase 3 Immunostimulant Dectin-1, Complement Receptor 3 (CR3) Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  2. RDC Clinical Pty Ltd · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Biotec Pharmacon ASA:

Cite this brief

Drug Landscape (2026). Biotec Pharmacon ASA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/biotec-pharmacon-asa. Accessed 2026-06-09.

Related